Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

2011740 citationsJournal Articlebronze Open Access

Authors

Ralph A. DeFronzo · The University of Texas Health Science Center at San Antonio

Devjit Tripathy · Texas Diabetes Institute

Dawn C. Schwenke · Arizona State University

MaryAnn Banerji · SUNY Downstate Health Sciences University

George A. Bray · Pennington Biomedical Research Center

Thomas A. Buchanan · University of Southern California

Stephen Clement

Abstract

As compared with placebo, pioglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus by 72% but was associated with significant weight gain and edema. (Funded by Takeda Pharmaceuticals and others; ClinicalTrials.gov number, NCT00220961.).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 12, pp. 1104-1115

DOI: 10.1056/nejmoa1010949

Field-Weighted Citation Impact: 47.13